Alison Siedor

Ali Siedor is an associate in Goodwin’s Intellectual Property Litigation practice and a member of the Life Sciences Disputes group. She focuses her practice on representing clients in intellectual property litigation, including patent litigation and post-grant invalidity proceedings. Ali’s experience includes representing life science companies in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA), as well as in arbitration proceedings relating to drug development and licensing disputes.

Ali’s experience includes pre-suit investigations, discovery, claim construction, motion practice, pretrial proceedings, trial, and post-trial proceedings, and has been involved in matters in district and state court, ITC investigations, ICC arbitrations, and PTAB proceedings. Some of Ali’s recent engagements include:

• Represented global generic pharmaceutical company in patent litigation involving generic pulmonary drug.  After a bench trial, the United States District Court for the District of Delaware found the asserted patents either noninfringed or invalid.   
• Represented global healthcare company in ITC investigation and inter partes review proceedings relating to patents covering a pre-filled syringe product.
• Represented Zealand Pharma A/S, a biotechnology research company, in an ICC arbitration concerning the company’s right to milestone and royalty payments for a peptide therapeutic under a licensing and collaboration agreement. The matter was resolved with a mutually acceptable settlement.
• Represented The Gillette Company in litigation filed against Dollar Shave Club, Inc., in which Gillette asserted infringement of a patent directed to razor blade coatings. The matter settled favorably before trial.

Pro bono

Ali is actively involved in Goodwin’s pro bono practice. She has worked on a variety of immigration-related matters, including Humanitarian Parole with a successful family reunification, and is currently pursuing SIJS and asylum petitions for an unaccompanied minor. Ali has also achieved successful outcomes for several social security disability matters and a VA disability matter. She currently serves as a member of the firm’s leadership team in partnership with GLAD’s Transgender ID Project. While a summer associate at Goodwin, Ali worked on a clemency petition for a federal inmate serving a life sentence for a nonviolent drug offense. The petition was approved and the client’s life sentence was commuted by President Obama.

Prior to and during law school, Ali worked as a registered nurse on a neurology, neurosurgery, and trauma floor.

While in law school, Ali externed at the Children’s Law Center as a guardian ad litem for children involved in custody disputes, volunteered with Greater Hartford Legal Aid, and served as the articles and commentary editor for the Connecticut Law Review.

Ali graduated with high honors from the University of Connecticut School of Law, and was a Pro Bono Honoree with over 100 hours of pro bono legal service.

• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” Thomson Reuters, January 2024
• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” Thomson Reuters, December 2022
• Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed.," Thomson Reuters, January 2021
• Co-Author, “Introduction to Biosimilars and Labeling Issues,” For the Defense, September 2020
• Co-Author, “Pandemic Spotlights Opportunistic Product Health Claims,” Law360, March 2020
• Co-Author, “Guide to Biosimilars Litigation and Regulation in the U.S.,” Thomson Reuters, November 2019
• Co-Author, “The 2018 Biosimilar Litigation Landscape: A Primer,” BioPharmadive, December 2017

Ali is also an editor of the firm’s biosimilars blog, Big Molecule Watch, which provides resources and observations through Goodwin’s active watch of legal, business and regulatory developments related to biologics, biosimilars, and the Biologics Price Competition and Innovation Act (BPCIA).